ImmunityBio Investors: Lawsuit Claims Anktiva’s Capabilities Were Overstated

ImmunityBio told investors it was sitting on a breakthrough. A cancer treatment with massive potential. Even framed as a path toward a cure.

But that promise did not match reality.

In January 2026, the company’s top executive went on a podcast claiming its drug Anktiva could treat all cancers and even prevent cancer. Big statements. Game changing. But behind the scenes, regulators saw something very different.

By March 2026, the FDA issued a warning letter saying those claims were false and misleading. The drug was only approved for a narrow type of bladder cancer. Not all cancers. Not prevention. Not a cure.

When the warning letter became public, the stock dropped about 21%.

Investors were stunned. Confidence cracked. The story unraveled fast.

Now, more investors are joining the lawsuit.